Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience (Q73446651)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 October 1999

Language	Label	Description	Also known as
English	Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience	scientific article published on 01 October 1999

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

expanded access

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J Bonneterre

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Spielman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J P Guastalla

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Marty

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P Viens

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P Chollet

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

H Roché

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P Fumoleau

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

L Mauriac

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

H Bourgeois

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Namer

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J P Bergerat

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J L Misset

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

L Trandafir

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Mahjoubi

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 October 1999

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

35

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1431-1439

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Systemic Therapy of Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Why event-free survival is better than tumor response or other measures of survival as an endpoint in cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900174-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(99)00174-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10673974%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73446651&oldid=2239387700"